Taken together, the study results present a novel mechanism of ING4-driven tumor-immune modulation and may offer potential opportunities for therapeutic intervention harnessing CD4 CTLs in ING4-deficient breast cancer. This evidence concerns the gene CD4 and breast carcinoma.